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Abstract     
Background 
There are no data on how fractional flow reserve (FFR) and instantaneous wave-free ratio 
(iFR) are associated with the degree of placebo-controlled efficacy of percutaneous coronary 
intervention (PCI) in stable single vessel coronary artery disease.  
Methods 
We report the association between pre-randomization invasive physiology within ORBITA, a 
randomized placebo-controlled trial which enrolled patients with stable angina and 
angiographically severe single vessel coronary disease clinically eligible for PCI. Patients 
underwent a pre-randomization research assessment of FFR and iFR. The operator was 
blinded to these values. Assessment of response variables, stress echo wall motion, symptom 
frequency, angina severity, and treadmill exercise time were performed pre-randomization 
and at blinded follow-up. Effects were calculated by analysis of covariance. The ability of FFR 
and iFR to predict placebo-controlled changes in response variables was tested using 
regression modelling. 
Results 
Invasive physiology data were available in 196 patients (103 PCI and 93 placebo). At pre-
randomization the majority of patients had Canadian Cardiovascular Society class II or III 
symptoms (150/196, 76.5%). Mean FFR and iFR were 0.69±0.16 and 0.76±0.22 respectively. 
97% of patients had one or more positive ischaemia tests. 
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The estimated effect of PCI on pre-randomization-adjusted total exercise time between the 
two arms was 20.7s (95% CI -4.0 to 45.5; p = 0.100) with no interaction of FFR (pinteraction=0.447) 
and iFR (pinteraction=0.262).  
Stress echo score decreased by 0.92 segment units (SD 1.48) in the PCI arm and had no 
significant change in the placebo arm (mean change +0.17, SD 1.12). PCI improved stress echo 
score more than placebo (1.06 segment units, 95% CI 0.69 to 1.43, p<0.00001). The placebo-
controlled effect of PCI on the stress echo score increased progressively with decreasing FFR 
(pinteraction<0.00001) and with decreasing iFR (pinteraction<0.00001). PCI did not improve angina 
frequency score significantly more than placebo (OR 1.62, 95% CI 0.95 to 2.76, p = 0.076) and 
there was no detectable evidence of interaction between either FFR (p interaction=0.843) or iFR 
(pinteraction=0.780). However, PCI was more likely to result in patient-reported freedom from 
angina than placebo (49.5% versus 31.5%; OR 2.47, 95% CI 1.30 to 4.72; p = 0.006) but neither 
FFR (pinteraction=0.692) nor iFR (pinteraction=0.759) modified this effect. 
Conclusions   
In patients with stable angina and severe single vessel coronary stenosis, the blinded effect 
of PCI was more clearly seen by stress echo score and by freedom from angina than by change 
in treadmill exercise time. Moreover, the lower the FFR or iFR, the greater the magnitude of 
stress echocardiographic improvement caused by PCI.  
Clinical Trial Registration 
URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT02062593          
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Clinical perspective 
What is new? 
 This report of ORBITA stratified by invasive haemodynamic measures of stenosis severity 
provides the first placebo-controlled evidence of the association between fractional flow 
reserve (FFR) and instantaneous wave-free ratio (iFR) and the magnitude of benefit 
attributable to percutaneous coronary intervention (PCI).  
 PCI improves ischaemia as assessed by dobutamine stress echocardiography. 
 PCI delivers freedom from angina to 20 absolute percentage points more patients than 
placebo (Number Needed to Treat = 5). 
 Pre-randomization FFR and iFR predict the placebo-controlled PCI effect on stress 
echocardiography. 
 Pre-randomization FFR and iFR did not predict the placebo-controlled PCI effect on 
symptoms or treadmill exercise time. 
What are the clinical implications? 
 PCI renders more patients free of angina than does placebo. 






Percutaneous coronary intervention (PCI) for stable single vessel coronary artery disease is 
widely accepted to alleviate angina based on unblinded clinical experience and unblinded 
randomized controlled trials.1-6 However, in the first placebo-controlled trial of PCI in stable 
single vessel coronary artery disease with patients and the medical team blinded to treatment 
allocation,  Objective Randomised Blinded Investigation with optimal medical Therapy of 
Angioplasty in stable angina (ORBITA), the placebo-controlled effect of PCI on the pre-
specified primary endpoint of exercise time at 6 weeks, by pre-specified statistical methods,7 
unexpectedly1 did not meet the criteria for statistical significance (point estimate 16.6s, 95% 
CI -8.9 to 42.0).8  
ORBITA used conventional, clinical criteria for eligibility for PCI, including symptoms and 
angiographic assessment. All patients were treated with guideline-directed medical therapy. 
In ORBITA, 94% of patients had one or more positive ischaemia tests. The unexpected result 
suggested that the commonly observed link between unblinded PCI of severe anatomic 
stenosis and improvement in symptoms and exercise capacity may be mediated by more 
complex pathways than a simple progression from anatomy to physiology to patient-
perceived benefit.  
PCI had a clearer effect on stress echocardiography than on treadmill exercise time or patient-
reported or physician-assessed symptoms. This increases the ability of stress 
echocardiography to distinguish between the efficacy of PCI across the disease spectrum. In 
double-blind evaluation, relief of the stenosis and its physiological consequences are the only 
contributors to symptom and exercise capacity improvement. This contrasts with unblinded 
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clinical practice and unblinded trials where the patient is told that the lesion is fixed, which 
may enhance the total therapeutic effect. 
A key aim of ORBITA was to document the association between fractional flow reserve (FFR) 
and instantaneous wave-free ratio (iFR) and the placebo-controlled response to subsequent 
PCI. To do this, the trial needed to store values of FFR and iFR before randomization and 
prevent these values from affecting treatment allocation. Therefore, after the decision for PCI 
had been made on current conventional clinical criteria, research FFR and iFR measurements 
were made but their values were not shown to the operator. This report, the physiology-
stratified analysis of ORBITA, describes how these blinded FFR and iFR values predict the 
placebo-controlled effect of PCI on stress echo score, patient-reported and physician-
assessed symptoms, quality of life, and treadmill exercise time. 
Methods 
Study design 
The design of the ORBITA trial has been previously described.8 In summary, patients with 
stable angina and angiographically severe single vessel coronary disease were enrolled at 5 
UK sites. At enrolment patients had assessment of symptoms by Canadian Cardiovascular 
Society (CCS) angina class and completed questionnaires on angina and quality of life.  The 
trial consisted of 2 consecutive phases: (1) six-week medical optimization phase of antianginal 
medication uptitration, ending with pre-randomization assessment and the blinded 
angiography procedure, and (2) six-week blinded follow-up phase ending with the follow-up 
assessment. The study was approved by a national ethics committee and all patients provided 
written consent.  
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The pre-randomization assessment included: (1) physician-assessed grading of angina 
severity (CCS class), (2) patient-reported symptoms using Seattle Angina Questionnaire,9 (3) 
quality of life using EuroQOL 5 (EQ-5D-5L) questionnaire, (4) cardiopulmonary exercise testing 
using the smoothed modified Bruce protocol10 which incorporates an initial 3 minutes of low 
level exercise that is not present in the standard Bruce protocol, and (5) dobutamine stress 
echocardiography.  
Invasive physiological assessment 
Patients then attended for the invasive procedure, which included research invasive pressure 
measurements and then randomization. Patients wore over-the-ear headphones playing 
music for auditory isolation.  Coronary angiography was performed via the radial or femoral 
approach.  
Invasive physiological assessment was performed with the clinical operator blinded to the 
results, as follows. The clinical operator, in all cases a consultant interventional cardiologist 
experienced in physiology measures, positioned the pressure wire radiographically but was 
not able to see the physiology display. A separate research interventional cardiologist was 
observing the physiology display to confirm signal quality and document the values digitally 
but did not convey the physiology values to the clinical operator. 
The reason to keep the clinical operator blinded to the physiology measures was to enable 
patients with a clinically representative range of values to be randomized in a single trial, with 
all decision making and outcome assessment identical regardless of physiological value. This 
distinguishes ORBITA from previous evaluations of physiology in which patients in different 
FFR ranges were randomized with different protocols for outcome assessment.4, 11  
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After administration of intracoronary nitrate and normalization of the pressure wire, FFR and 
iFR were measured using standard techniques with the wire placed at least 3 vessel diameters 
distal to the most distal stenosis. Intravenous adenosine was then administered 
(140mcg/kg/min) via a femoral venous line or antecubital fossa vein and FFR was measured. 
Drift check was recorded.  
The operator then waited for 10 minutes. Intracoronary nitrate was re-administered, the wire 
was re-normalized and re-advanced into the same distal position using cine images from the 
first physiological assessment as a guide. iFR and FFR measurements were repeated. Drift 
check was once again performed.  
If at any stage there was significant wire drift (Pd/Pa ratio outside the range 1.00 ± 0.02), the 
wire was re-normalized and iFR and FFR measurements were repeated with final drift check. 
The mean values of FFR and of iFR were used for analysis.    
Blinding and randomization 
After physiological assessment, patients received incremental doses of intravenous 
benzodiazepine and opiate until a deep level of conscious sedation was achieved. Once this 
was confirmed, they were then randomized to receive PCI or placebo procedure.  
If randomized to placebo no further invasive measurements were made and the patient 
remained in the catheter laboratory for a minimum of 15 minutes. 
If randomized to PCI, this was performed using angiographic guidance with drug eluting stents 
implanted and complete angiographic revascularization mandated. Post-dilatation was 
 9 
recommended, and intravascular ultrasound or optical coherence tomography were used at 
the operator’s discretion. 
After PCI, iFR and FFR were re-measured, and again the clinical operator was blinded to the 
results.  
The patient and all subsequent medical caregivers were blinded to the treatment allocation 
using methods described previously.8  
Study endpoints and follow-up 
At the end of the blinded follow-up period patients re-attended to have repeat assessment 
of questionnaires, cardiopulmonary exercise testing and stress echocardiography. They were 
then unblinded and returned to routine clinical care pathways. Patients in the placebo arm 
were able to receive PCI if they wished.  
Dobutamine stress echocardiography 
Rest and stress cardiac regional wall motion was assessed using dobutamine stress 
echocardiography. The test was performed by a physician and sonographer. The patient, 
physician and sonographer were all blinded to allocation arm. 
Analysis was also performed blinded to treatment allocation and phase (pre-randomization 
or follow up), using an online reporting tool. In the original ORBITA publication, analysis had 
been performed by 2 imaging consultants (RA and DF).  
For the present physiology-stratified analysis of ORBITA, each scan received 12 opinions. Each 
scan was examined twice by 6 imaging consultants (RA, DF, GC, SK, JS, and NK) who were 
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blinded to treatment allocation, time-point of the scan, their colleagues’ opinions, and (on 
the second viewing) their own first opinion. 
In this physiology-stratified analysis of ORBITA, for ease of reader interpretation, stress echo 
results are presented in a manner that represents the number of hypokinetic segments (with 
akinetic segments scoring double, and dyskinetic scoring triple, and aneurysmal segments 
scoring quadruple). In detail, the left ventricle was divided into the standard 17 segments. 
Wall motion was scored as follows: normal = 0, hypokinetic = 1, akinetic = 2, dyskinetic = 3 or 
aneurysmal = 4. These individual wall abnormality scores at peak stress were summed, giving 
a total that could range from 0 (for normal) to theoretically 317. Both opinions from all 6 
consultants were then averaged. This stress echo score can be broadly converted to classical 
wall motion score index as follows: wall motion score index = 1+(stress echo score)/17. 
Cardiopulmonary exercise testing 
All cardiopulmonary exercise tests investigations were performed using the QUARK CPET 
breath-by-breath metabolic measurement system (COSMED, Rome, Italy). Cardiopulmonary 
exercise testing was performed using the smoothed modified Bruce protocol and endpoints 
reported as previously described.8 
Statistical analysis 
For physiology-stratified analysis of ORBITA the data available consisted of all patients with 
at least one form of invasive physiological assessment at pre-randomization. Summary 
statistics were presented as appropriate for baseline characteristics.  
The main ORBITA report applied unpaired t-tests of change scores for continuous variables 
because that was the pre-specified method of analysis.7 However, regression models (a 
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generalised form of analysis of covariance) provide increased statistical power, and allow the 
interaction between FFR and iFR and benefit to be tested, and so these are used for this 
physiology-stratified analysis of ORBITA.12 
The Seattle Angina Questionnaire scales for angina frequency, physical limitation and quality 
of life scores were derived from the patient’s answers in accordance with published 
guidelines.13 Freedom from angina was calculated from the Seattle Angina Questionnaire.  
For each endpoint, a model was fitted. For the continuous endpoints of EQ-5D-5L descriptive 
system and visual analogue scores, Seattle Angina Questionnaire physical limitation and 
quality of life scores, total exercise time and stress echo score linear models were used.  
For the ordinal variables of Seattle Angina Questionnaire angina frequency and freedom from 
angina, and CCS class a proportional odds ordinal logistic model was used. The proportional 
odds ordinal logistic model accommodates the strange statistical distribution (and possible 
floor and ceiling effects) of variables such as angina frequency.  It involves no categorization 
and is statistically very efficient while only using the rank order of frequency across 
patients.  The commonly used Wilcoxon-Mann-Whitney 2-sample rank-sum test is a special 
case of this ordinal logistic model when there is only one covariate and it is binary.  Even if 
the response variable were normally distributed, the proportional odds model has efficiency 
of 3/π or about 0.95. 
For both continuous and categorical outcome variables we modelled the follow-up value 
conditioned on the pre-randomization value transformed by a restricted cubic spline with 
three parameters, and randomization arm. A model was then fitted for each outcome variable 
with pre-randomization FFR or iFR interacting with the randomization arm and the pre-
randomization value of the outcome variable with a restricted cubic spline with three 
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parameters, i.e. the shape of effect was allowed to vary over treatments.12 Graphs of the 
endpoints against FFR and iFR, and the contrast between the arms was generated adjusting 
for the median value of the pre-randomization value.  
All analyses were performed using the open-source statistical environment “R”,14 with the 
package “rms” for regression modelling,15 and “ggplot2” for graphs.16  
The data, analytical methods, and study materials will not be made available to other 
researchers for purposes of reproducing the results or replicating the procedure.  
Results 
ORBITA enrolled 230 patients. After the medical optimization phase 200 patients were 
randomized to PCI (n=105) versus placebo (n=95). Four patients in the ORBITA dataset did not 
have physiological assessment because in 3 patients the lesion could not be crossed with the 
pressure wire, and in 1 patient crossing of the lesion with the pressure wire caused intimal 
disruption requiring immediate PCI. Therefore, 196 randomized patients had invasive 
physiological assessment and were available for the physiology-stratified analysis of ORBITA 
(103 in PCI arm and 93 in placebo arm). Within this dataset there were 2 patients in whom 
we were unable to elicit a hyperemic response with intravenous or intracoronary adenosine, 
and therefore only iFR data were obtained. 
Patient demographics 
Patient demographics are shown in Table 1. The majority of patients (98.1% in PCI arm and 
96.8% in placebo arm) had physician-assessed CCS class II or III angina severity at enrolment.  
Medical therapy  
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At pre-randomization, the majority of patients were taking more than 2 antianginal 
medications (85.4% in PCI vs. 90.3% in placebo, Table A1 in Supplementary Appendix). 97.1% 
of patients in the PCI arm and 96.8% in the placebo arm were taking dual antiplatelet therapy. 
Three patients in the PCI arm and 3 patients in the placebo arm were only on a single 
antiplatelet agent because of aspirin intolerance. After the medical optimization phase, at 
pre-randomization, the majority of patients had CCS class II or III symptoms (150/196, 76.5%) 
(Table A2 in Supplementary Appendix) and the 83.0% (161/194) of patients reported one or 
more episodes of angina in the last 4 weeks (Table A3 in Supplementary Appendix). 
Procedural demographics 
Procedural demographics are shown in Table 2. The median time between the first diagnostic 
angiogram and the pre-randomization angiogram was 54 days (IQR 45 to 64) for the complete 
group. The majority of patients (69.9%) had lesions in the left anterior descending artery, 
these lesions were in the ostium or proximal segment of the left anterior descending artery 
in 55.5% and mid left anterior descending artery in 51.8%.  
The FFR and iFR distributions are shown in Figures A1 and A2 in Supplementary Appendix. The 
mean FFR was 0.69 (SD 0.16): 145/194 (74.7%) had FFR≤0.80, mean 0.62 (SD 0.13); the 
remainder had mean FFR 0.87 (SD 0.04). The mean iFR was 0.76 (SD 0.22): 136/196 (69.4%) 
had iFR≤0.89, with mean 0.69 (SD 0.21); the remainder had mean iFR 0.94 (SD 0.03). 
Overall 191 patients (97%) had 1 or more positive ischemia tests by time of randomization; 
these consisted of a pre-enrolment clinical test, research stress echo, FFR≤0.80 or iFR≤0.89. 
The angiographic images of the remaining 5 patients are shown in Figure A3 in Supplementary 
Appendix. 
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All patients in the PCI arm had drug eluting stents implanted. Post-dilatation was performed 
with a non-compliant balloon in 86 (83.5%) of these stents. Mean post-PCI FFR was 0.90 (SD 
0.06) and post-PCI iFR 0.95 (SD 0.04). Six (6.3%) patients had FFR≤0.80 post procedure: their 
mean FFR was 0.76 (SD 0.06). Five (4.9%) patients had iFR≤0.89 post procedure: their mean 
iFR was 0.86 (SD 0.04). 
Study endpoints 
Exercise time 
Paired exercise time data were available for 190 patients in the physiology-stratified analysis 
of the ORBITA dataset (102 in PCI arm and 88 in placebo arm). The estimated effect of PCI 
over placebo on exercise time using regression modelling was 20.7 seconds (95% CI -4.04 to 
45.5; p=0.100, Table A4 in Supplementary Appendix). For this relatively small effect, there 
was no detectable evidence of interaction between either FFR (pinteraction=0.447) or iFR 
(pinteraction=0.262) and the effect of PCI on exercise time increment (Figures 1A and 1B).  
Dobutamine stress echocardiography  
The stress echo dataset consists of 159 patients (90 PCI, 69 placebo), each with pre-
randomization and follow-up scans, with each scan having reported twice by 6 imaging 
consultants. Stress echo score decreased by 0.92 segment units (SD 1.48) in the PCI arm and 
had no significant change in the placebo arm (mean change +0.17, SD 1.12). Overall, PCI 
improved the stress echo score when compared to placebo (difference 1.06 segment units, 
95% CI 0.69 to 1.43; p < 0.00001, Table A4 in the Supplementary Appendix).  
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There was an interaction between FFR and the stress echo improvement from PCI over 
placebo (pinteraction<0.00001), with a progressively larger improvement at lower pre-
randomization FFR values (Figure 2A) 
Similarly, there was an interaction between iFR and the stress echo improvement 
(pinteraction<0.00001, Figure 2B), with a progressively larger improvement at lower pre-
randomization iFR values.  
 
Patient-reported symptoms and quality of life 
Paired patient-reported data at pre-randomization and follow-up from the Seattle Angina 
Questionnaire was available in 192 patients (103 in the PCI arm and 89 in the placebo arm).  
There was no statistically significant evidence that PCI improved Seattle Angina Questionnaire 
angina frequency score more than placebo (OR 1.62; 95% CI 0.95 to 2.76; p=0.076, Table A4 
in Supplementary Appendix). This odds ratio does not come from a dichotomization of angina 
frequency but from the proportional odds model and involves the ratio of odds of a frequency 
> f for two groups, for any non-zero f. 
For this non-significant effect, there was no detectable evidence of interaction between 
either FFR (pinteraction=0.843) or iFR (pinteraction=0.780) and the effect of PCI on angina frequency score 
(Figures 3A and 3B).  
PCI was more likely to result in patient-reported freedom from angina than placebo (OR 2.47; 
95% CI 1.30 to 4.72; p = 0.006, Figure 4; Tables A4 and A5 in Supplementary Appendix). 
Complete freedom from angina was achieved in more patients in the PCI arm compared to 
the placebo arm (49.5% versus 31.5%, p=0.006). There was no detectable evidence of 
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interaction between either FFR or iFR and the effect of PCI on the likelihood of patient-
reported freedom from angina (pinteraction=0.692; Figure 5A and pinteraction=0.759; Figure 5B).  
PCI did not improve Seattle Angina Questionnaire physical limitation score more than 
placebo: point estimate 2.59 units (95% CI -2.93 to 8.10; p = 0.356, Table A4 in Supplementary 
Appendix). For this non-significant effect, there was no detectable evidence of interaction 
between either FFR (pinteraction=0.806) or iFR (pinteraction=0.616) and the effect of PCI on physical 
limitation score (Figures A4A and A4B in Supplementary Appendix). 
PCI did not improve Seattle Angina Questionnaire quality of life score more than placebo 
(2.15; 95% CI -3.75 to 8.05; p = 0.474, Table A4 in Supplementary Appendix). For this non-
significant effect, there was no detectable evidence of interaction between either FFR 
(pinteraction=0.317) or iFR (pinteraction=0.240) and the effect of PCI on quality of life score (Figures A5A 
and A5B in Supplementary Appendix). 
Paired EQ-5D-5L data was available for 189 patients (102 in the PCI arm and 87 in the placebo 
arm).  
PCI did not improve EQ-5D-5L descriptive scale more than placebo: point estimate 0.001 (95% 
CI -0.039 to 0.042; p=0.951, Table A4 in Supplementary Appendix). For this non-significant 
effect, there was no detectable evidence of interaction between either FFR (pinteraction=0.726) or 
iFR (pinteraction=0.934) and the effect of PCI on EQ-5D-5L descriptive scale (Figures A6A and A6B in 
Supplementary Appendix). 
PCI did not improve EQ-5D-5L visual analogue score more than placebo: point estimate 1.22 
(95% CI -3.47 to 5.90; p=0.610, Table A4 in Supplementary Appendix). For this non-significant 
effect, there was no detectable evidence of interaction between either FFR (pinteraction=0.397) or 
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iFR (pinteraction=0.400) and the effect of PCI on EQ-5D-5L visual analogue score (Figures A7A and 
A7B in Supplementary Appendix). 
 
Physician-assessed symptoms 
Paired CCS data were available for 192 patients in the physiology-stratified analysis of the 
ORBITA dataset (103 in PCI arm and 89 in placebo arm). At enrolment there were no patients 
with CCS 0, at pre-randomization 8.74% patients in the PCI arm and 14.0% patients in placebo 
arm were classified as CCS 0, by follow-up 39.8% of patients in the PCI arm and 28.0% of 
patients in placebo arm were classified as CCS 0 (p=0.132, Table A2 in Supplementary 
Appendix). PCI did not improve CCS class more than placebo (OR 0.73, 95% CI 0.43 to 1.25; p 
= 0.254, Table A4 in Supplementary Appendix). For this non-significant effect, there was no 
detectable evidence of interaction between either FFR (pinteraction=0.876) or iFR (pinteraction=0.841) and 
the effect of PCI on change in CCS class (Figures 6A and 6B).  
 
Using FFR and iFR dichotomously 
Although this study was intended to treat FFR and iFR as continuous variables, some readers 
may wish to see the PCI effect in patients above and below certain FFR and iFR values. These 
data are presented in Tables A6 to A9 in the Supplementary Appendix.  
Additionally, the endpoint analysis and PCI effects for dichotomous FFR and iFR in only those 
patients with CCS class I-IV symptoms at pre-randomization are presented in Tables A10 to 




This physiology-stratified analysis of ORBITA provides placebo-controlled data on the 
association between pre-randomization invasive physiology and the efficacy of PCI in stable 
single vessel coronary artery disease. The severe anatomical stenosis was dramatically 
improved, and there were progressively smaller effects along a notional mechanistic 
pathway, including invasive haemodynamic measurements, myocardial perfusion and finally 
symptoms.  
The initial anatomical and haemodynamic effects of PCI were large. The resultant stress echo 
score was very clearly improved by PCI versus placebo; and the more severe the FFR and iFR, 
the larger the PCI effect on stress echo score.  
Of patient-reported change in symptoms, the most binary is absence versus presence of 
symptoms. On this endpoint of patient-reported freedom from angina, PCI was more effective 
than placebo. Indeed, one in five more patients became free of angina with PCI than with 
placebo procedure.  However, Seattle Angina Questionnaire physical limitation score and 
quality of life scores and EQ-5D-5L quality of life score did not show an effect of PCI beyond 
placebo. Nor could physician-assessment of patient symptoms (CCS) or treadmill exercise 
time detect the effect of PCI beyond placebo.  
Neither exercise time nor symptom endpoints showed any association between FFR or iFR 
and the effect of PCI. This means that there is no sign of the unexpected primary result of 
ORBITA8 being the consequence of enrolling the full spectrum of patients clinically eligible for 
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single vessel PCI including those who met the criteria despite their blinded research FFR being 
>0.80.  
This analysis of ORBITA was intended to treat FFR and iFR as continuous variables. 
Dichotomous analysis of continuous variables loses power and precision but is often 
recommended, reported and discussed. There is no established cut-point for angina. We 
therefore present in the Supplementary Appendix results for the patients dichotomised using 
a range of cut-points including those commonly recommended for the decision for PCI.  
The blinded effect size calculated from ORBITA is much smaller than the 96s exercise time 
benefit calculated from the unblinded ACME trial which was of similar size, enrolled patients 
with similar exercise capacity, and used the same statistical method as pre-specified in 
ORBITA.7 One possibility is that patients being told their lesion had been fixed or not fixed 
makes a difference to their exercise capacity. An alternative possibility is that the ~6-fold 
larger effect size of ACME was because it used plain balloon angioplasty rather than modern-
day stenting or that its 6-month time-point was necessary for the lesion to be properly 
relieved. Another possibility that has been proposed is that the large effect size was due to 
differences in medical therapy between arms. We do not believe this is plausible because the 
ACME PCI arm received less nitrates (p<0.01), beta-blockers (p<0.01), and calcium channel 
antagonists (p<0.01). A final possibility is that patients in the PCI arm may have reduced their 
beta-blocker usage or had increased their habitual exercise as a result of knowing had had 
PCI.17 
It is still not clear why the objective relief of anatomical, haemodynamic and stress 
echocardiographic abnormalities did not translate as well as hoped into patient-centred 
endpoints under blinded conditions. However, on the most unambiguous dichotomous 
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patient-centred endpoint, freedom from angina, there was a statistically significant 
improvement with PCI with a large absolute improvement. 
ORBITA was analysed as pre-specified,7 with t-test of change scores in the objective and 
continuous variable of exercise time. An alternative statistical approach, applied in this 
stratified analysis of ORBITA, is regression modelling, which offers advantages including the 
ability to adjust appropriately for pre-randomization values and to measure the interaction 
between FFR and iFR on the effect size. The increment of exercise time with PCI over placebo, 
regardless of method of analysis, was smaller than might have been expected based on 
previous unblinded evidence.1  
Exercise treadmill time has a long track record of detecting the effect of anti-anginal 
medication against placebo. However, PCI opens the stenosis and anti-anginals do not. This 
may explain why treadmill exercise time under placebo-controlled conditions responds 
differently to PCI than to anti-anginal medications. 
Ultimately the patient-centred symptomatic aim is to reduce angina and ideally render 
patients free from angina. Under blinded conditions more patients directly reported freedom 
from angina with PCI than with placebo. It is possible that this endpoint detected an effect of 
PCI because it is easier to be sure that one is free of angina than to reliably distinguish 
different levels of pain.18  
The physiology-stratified analysis of ORBITA provides the first placebo-controlled evidence of 
the efficacy of PCI on stress echo score and shows that the degree of benefit is greatest in 
those patients with the highest degree of ischaemia measured by invasive physiology.  It 
additionally provides data that patients in the PCI arm were more likely to report freedom 
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from angina at follow-up compared to placebo but that this effect was not predicted by pre-
randomization FFR and iFR values. 
 
Study limitations 
This physiology-stratified analysis of ORBITA is a sub-analysis describing the 196 patients for 
whom invasive physiology measurements were available, only 98% of the 200 randomized in 
ORBITA. Moreover, the effect size of PCI on treadmill exercise time fell far short of our 
expectations based on unblinded prior research and, therefore, this endpoint is not powered 
for probing the association between invasive physiology and placebo-controlled response to 
PCI.1 Although it was the pre-specified primary endpoint, exercise time was one of the least 
influenced markers. The same can be said for symptoms.  
This study intentionally included a representative spectrum of patients appropriate for clinical 
single vessel PCI. Of them, 97% had ischemia documented on one or more non-invasive or 
invasive tests at the time of randomization, and the 5 remaining angiograms are shown 
(Supplementary Appendix). FFR was measured not19 for clinical decision-making (since all 
patients were already eligible), but rather for research purposes to study the association 
between FFR and the placebo-controlled effect of PCI.  
Dichotomising a continuous variable removes most of its information content12 but we 
present the dichotomous analyses because readers may be curious. There has been no 
previous blinded identification of a “best” threshold of FFR or iFR for angina relief from PCI. 
We therefore present data for multiple thresholds that include the thresholds recommended 
from unblinded trials. 
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No study can exclude the possibility of a weak association between variables. This study 
merely shows that there is no threshold of FFR or iFR below which PCI consistently improves 
exercise time (or symptoms) more than placebo and above which it consistently does not. 
However, there is a marked association between FFR or iFR and change in stress echo score 
(p<0.00001, p<0.00001) which indicates that for this endpoint the study is not underpowered. 
In the primary ORBITA report, stress echocardiography data was presented as pre-specified, 
in the form of wall motion score index. Normal was 1.0, a single segment of hypokinesia was 
scored as 1.0588 and 2 segments of hypokinesia were scored as 1.1176. Interpretation of such 
scores by non-imaging specialists can be difficult. To aid interpretation, in this report, we 
score normal as 0, 1 segment of hypokinesia as 1, 2 as 2 and so on. This is a simple linear 
transformation that has no effect on the statistics.  
For the primary ORBITA report, each stress echocardiogram was only scored by 2 consultants 
blinded to treatment allocation and time-point. In this physiology-stratified analysis of 
ORBITA, each stress echocardiogram was scored by 6 consultants, twice each, blinded to 
treatment allocation and time-point. This is different from common clinical practice but 
maximises the statistical power of the analysis.  
All patients were considered by the physician to have angina at enrolment (i.e. were CCS class 
1 or above), but in the patient-reported question on frequency of angina from the Seattle 
Angina Questionnaire, 14.1% of patients indicated no symptoms of angina in the immediately 
preceding four weeks. We cannot tell whether this was caused by pre-enrolment anti-anginal 
therapy, by self-limiting of day-to-day activities, or indeed the unique way the study was 
performed with close direct supervision by the research team. The proportions of patients in 
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CCS 0 at pre-randomization were 11.5% in ORBITA, 9% in ACME, 11.2% in FAME-2 and 12.5% 
in COURAGE.20, 21 
A significant proportion of patients in this physiology-stratified analysis of ORBITA continued 
to report episodes of angina after PCI. After blinded PCI, physician-assessed CCS II-III in the 
PCI arm was 47% in ORBITA.8, 22 For comparison, after unblinded PCI, physician-assessed CCS 
II-III was 57.1% in the second Randomised Intervention Treatment of Angina (RITA-2) at 6 
months,2 45.5% in Medicine, Angioplasty, or Surgery Study (MASS-II) at 1 year,23 and 34% in 
COURAGE at 1 year.3 The one dramatically different result was from FAME-2 which reported 
5.9%.24  
The trial design only asked patients to remain blinded and randomized for 6 weeks, because 
we expected a large benefit from PCI and wanted to ensure recruitment of severe coronary 
stenoses as shown in the ORBITA appendix. All patients were unblinded. The placebo arm 
patients returned to their normal clinical care. The results of ORBITA were not yet known. 
Most (77/91, 85%) control patients in ORBITA chose to have PCI. In a placebo-controlled trial 
the scientific value of symptom assessment is during the blinded period. 
 
Conclusions 
PCI relieved not only the anatomical and haemodynamic features of the coronary stenosis 
but also normalized the stress echocardiography. PCI caused more patients to become free 
from angina than did placebo. 
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Progressively lower pre-randomization FFR and iFR predicted a progressively larger effect of 
PCI versus placebo on stress echo ischaemia. They did not predict the PCI effect on symptoms, 
quality of life or treadmill exercise time.  
The effect of PCI on endpoints, and the extent to which this effect is associated with FFR and 
iFR, declines progressively along the pathway from resolution of angiographic stenosis, 
through haemodynamics and myocardial performance, through to patient experienced 
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n (%)  
Age (yrs)  65.7±9.5 66.1±8.3 65.9±9.0 
Male 72 (69.9) 71 (76.3) 143 (73.0) 
Hypertension 70 (68.0) 65 (69.9) 135 (68.9) 
Hypercholesterolemia 79 (77.0) 61 (65.6) 140 (71.4) 
Diabetes 15 (14.6) 21 (22.6) 36 (18.4) 
Previous MI 4 (3.9) 7 (7.5) 11 (5.6) 
Previous PCI 10 (9.7) 14 (14.1) 24 (12.2) 
CCS class  
   
I 2 (1.9) 3 (3.2) 5 (2.5) 
II 62 (60.2) 53 (57.0) 115 (58.7) 
III 39 (37.9) 37 (39.8) 76 (38.8) 
Angina duration (months) 
Mean (SD) 
9.54±15.8 8.45±7.59 9.03±12.6 
Positive functional test  55 (53.4) 42 (45.2) 97 (49.5) 
ETT 26 (25.2) 17 (18.3) 43 (21.9) 
MIBI 10 (9.7) 11 (11.8) 21 (10.7) 
DSE 19 (18.4) 13 (14.0) 32 (16.3) 
MRI perfusion 0 (0) 1 (1.1) 1 (0.5) 
 
MI= Myocardial infarction 
PCI= Percutaneous coronary intervention 
CCS= Canadian Cardiovascular Society Angina class 
SAQ= Seattle angina questionnaire 
ETT= Exercise tolerance test 
MIBI= Nuclear medicine myocardial perfusion scan 
DSE= Dobutamine stress echocardiography 
MRI= Magnetic resonance imaging 
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Left anterior descending  72 (69.9) 65 (70.0) 137 (69.9) 
Ostial/proximal 
 
46 (44.7) 30 (32.3) 76 (38.8) 
Mid 
 
33 (32.0) 38 (40.9) 71 (36.2) 
Distal 
 
4 (3.9) 8 (8.6) 12 (6.1) 
Right coronary 
 
16 (15.5) 15 (16.1) 31 (15.8) 
Circumflex 
 
9 (8.7) 9 (9.7) 18 (9.1) 
First obtuse marginal 
 
3 (2.9) - 3 (1.5) 
First diagonal 
 
2 (1.9) 2 (2.2) 4 (2.0) 
Intermediate 
 
1 (1.0) 2 (2.1) 3 (1.5) 
Serial lesions 
 
17 (16.5) 12 (12.9) 29 (1.5) 
No. pts with diameter stenosis ≥50% by QCA 
 
87 (84.4) 79 (85.0) (84.7) 
Diameter stenosis by QCA 
Mean (SD) 

















No. pts with FFR ≤0.80 
 




No. pts with iFR ≤0.89 
 
68 (66.0) 68 (73.1) 136 (69.4) 





Stent diameter (mm) 
Median (IQR) 
























QCA= Quantitative coronary angiography 
FFR= Fractional flow reserve 
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Figure 1.  
A. Relationship of change in pre-randomization to follow up total exercise time and pre-
randomization FFR by randomization arm. There is no discernible dependency on pre-
randomization FFR. 
B. Relationship of change in pre-randomization to follow up total exercise time and pre-
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Figure 2. 
A. Relationship of treatment difference in stress echo score and pre-randomization FFR by 
randomization arm. At the right, with FFR1.0, the curve is 0, indicating that there is no 
difference between PCI and placebo. The shaded area represents the 95% CI for the estimate 
of this mean effect. At progressively lower FFR values, there is a progressively larger 
difference between PCI and placebo on the endpoint. This progressive tendency for larger 
effects on stress echo score with lower pre-randomization FFR has pinteraction<0.00000001.  
B. Relationship of treatment difference in peak stress echo score and pre-randomization iFR 
by randomization arm. At the right, with iFR1.0, the curve is 0, indicating that there is no 
difference between PCI and placebo. The shaded area represents the 95% CI for the estimate 
of this mean effect. At progressively lower iFR values, there is a progressively larger difference 
between PCI and placebo on the endpoint. This progressive tendency for larger effects on 
stress echo score with lower pre-randomization iFR has pinteraction<0.00000001.  
The stress echo score can be converted to classical Wall Motion Score Index as follows. Wall 
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Figure 3. 
A. Relationship of treatment difference in Seattle Angina Questionnaire angina frequency 
score and pre-randomization FFR by randomization arm. There is no discernible dependency 
on pre-randomization FFR.  
B. Relationship of treatment difference in Seattle Angina Questionnaire angina frequency 
score and pre-randomization iFR by randomization arm. There is no discernible dependency 
on pre-randomization iFR. 
The vertical axis shows the impact of PCI rather than placebo on the natural logarithm of the 
odds ratio for improvement versus deterioration. Upward indicates greater odds of 
improvement with PCI than with placebo. An odds ratio of 1 means no difference between 
arms. An odds ratio of 2 would indicate the odds are two-fold more favourable with PCI than 








Percentage of patients free of patient-reported angina at enrolment, pre-randomization and 
follow-up per study arm from Seattle Angina Questionnaire. Proportional odds model for 
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Figure 5. 
A. Relationship of treatment difference in patient-reported freedom from angina from Seattle 
Angina Questionnaire at follow-up to pre-randomization FFR by randomization arm. There is 
no discernible dependency on pre-randomization FFR. 
B. Relationship of treatment difference in patient-reported freedom from angina from Seattle 
Angina Questionnaire at follow-up to pre-randomization iFR by randomization arm. There is 
no discernible dependency on pre-randomization iFR. 
Upward indicates greater odds of achievement of angina freedom with PCI than with placebo. 
An odds ratio of 1 means no difference between arms. An odds ratio of 2 would indicate the 
odds are two-fold more favourable with PCI than with placebo. The improvement or 
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Figure 6. 
A. Relationship of treatment difference in physician-assessed Canadian Cardiovascular 
Society class (CCS) at follow-up to pre-randomization FFR by randomization arm. There is no 
discernible dependency on pre-randomization FFR.  
B. Relationship of treatment difference in physician-assessed Canadian Cardiovascular Society 
class (CCS) at follow-up to pre-randomization iFR by randomization arm. There is no 
discernible dependency on pre-randomization iFR.  
The vertical axis shows the impact of PCI rather than placebo on the natural logarithm of the 
odds ratio for increase versus decrease in CCS class. Upward indicates greater odds of 
increase with PCI than with placebo. An odds ratio of 1 means no difference between arms. 
The increase or decrease is calculated using an ordinal cumulative probability model.25 
 
 
